To support drug discovery projects in oncology, we perform high-content analysis either in cellular models of human tumors in 2D or 3D, or directly in tumor tissues and blood samples. Combining a panel of validated assays for immediate performance and more than 10-year experience in assay development, we assist pharmaceutical companies and academic researchers in the discovery of new cancer drug targets, the identification of new anticancer compounds, and the quantitative analysis of novel cancer biomarkers.
CELL PHYSIOLOGY (PROLIFERATION & CELL CYCLE/MIGRATION, ADHESION & DIFFERENTIATION/ANGIOGENESIS)
Clonogenicity |
Multiple cellular models |
PF 10.4 |
Cell cycle |
Multiple cellular models |
PF 3.8 |
Cell proliferation |
Multiple cellular models |
PF 3.9 |
Migration |
Multiple cellular models |
PF 3.14 |
Invasion (3D) |
Multiple cellular models |
PF 3.15 |
Angiogenesis (endothelial/microendothelial tube formation) |
HUVECs/HDMECs Cells/R/6A cells |
PF 10.8 |
c-myc expression |
Multiple cellular models |
PF 10.25 |
Pan keratin expression |
Multiple cellular models |
PF 10.13 |
CELL STRESS AND METABOLISM
Intracellular reactive oxygen species |
Multiple cellular models |
PF 3.11 |
y-secretase activity |
Established HeLa cell clone |
PF 3.13 |
Lipid peroxidation |
Multiple cellular models |
PF 3.18 |
Glutathione (GSH), |
Multiple cellular models |
PF 3.28 |
Hypoxia analysis/quantification |
Multiple cellular models |
PF 3.20 |
Heme Oxygenase 1 expression |
Multiple cellular models |
PF 3.25 |
MnSOD induction |
Multiple cellular models |
PF 10.43 |
Protein-protein interaction |
Multiple cellular models |
PF 10.28 |
cAMP quantification |
Multiple cellular models |
PF 3.27 |
Calcium signaling |
Multiple cellular models |
PF 3.33 |
FLIP expression |
Multiple cellular models |
PF 10.27 |
Line-1 expression |
Multiple cellular models |
PF 10.26 |
c-myc expression |
Multiple cellular models |
PF 10.25 |
Src expression |
Multiple cellular models |
PF 10.24 |
FRS phosphorylation |
Multiple cellular models |
PF 10.23 |
PLCy phosphorylation |
Multiple cellular models |
PF 10.21 |
Cytochrome c release |
Multiple cellular models |
PF 10.5 |
Fas expression/phosphorylation |
Multiple cellular models |
PF 10.16 |
Protein synthesis quantification |
Multiple cellular models |
PF 10.46 |
Lipid, intracellular accumulation: |
Multiple cellular models |
PF 3.29 |
Lipid, intracellular accumulation: phospholipids |
Multiple cellular models |
PF 3.30 |
NAD(P)H / FAD |
Multiple cellular models |
PF 3.31 |
DNA DAMAGE, CELL DEATH AND APOPTOSIS
NEW ! Immune cell killing |
RKO Cell line | PF 10.47 |
Caspase 3/7 activity |
Multiple established cell clones | PF 3.1 |
Caspase 3/7 activation | Multiple cellular models | PF 3.2 |
Mitochondrial membrane potential |
Multiple cellular models |
PF 3.3 |
Cytolysis |
Multiple cellular models |
PF 3.4 |
Calpain activity |
Multiple established cell clones |
PF 3.12 |
Autophagy (LC3B) |
Multiple cellular models |
PF 3.17 |
DNA oxidation |
Multiple cellular models |
PF 10.6 |
Histone H3 acetylation (Lys9) |
Multiple cellular models |
PF 10.19 |
Micronuclei |
Blood |
PF 10.22 |
Caspase 9 activation |
Multiple cellular models |
PF 10.45 |
PARP (cleaved) |
Multiple cellular models |
PF 10.44 |
dnMT1 expression |
Multiple cellular models |
PF 10.37 |
PCNA expression |
Multiple cellular models |
PF 10.34 |
Bad expression |
Multiple cellular models |
PF 10.33 |
Bcl2 expression |
Multiple cellular models |
PF 10.32 |
Bax activation |
Multiple cellular models |
PF 10.31 |
Mcl1 expression |
Multiple cellular models |
PF 10.30 |
Noxa |
Multiple cellular models |
PF 10.29 |
Cytochrome c release |
Multiple cellular models |
PF 10.5 |
Apoptosis (Annexin V) quantification |
Multiple cellular models |
PF 10.2 |
Caspase 8 activity |
Multiple cellular models |
PF 10.3 |
RECEPTOR PHARMACOLOGY AND SIGNALING PATHWAYS
Glucocorticoid receptor subcellular translocation |
AtT20 primary rat nuclear translocation pituitary cells |
PF 3.26 |
Androgen receptor nuclear translocation |
LnCaP cell line |
PF 10.1 |
Prostate Specific Antigen (PSA) expression | LnCap cell line | PF 10.15 |
p21 quantification |
Multiple cellular models |
PF 10.18 |
p38 phosphorylation |
Multiple cellular models |
PF 10.20 |
p53 expression level/activation |
Multiple cellular models |
PF 10.17 |
NF kB activation |
Multiple cellular models |
PF 3.23 |
Ras expression |
Multiple cellular models |
PF 10.14 |
MEK phosphorylation |
Multiple cellular models |
PF 10.36 |
ERK activation (pERK1/2) |
Multiple cellular models |
PF 3.27 |
cAMP quantification |
Multiple cellular models |
PF 3.40 |
Calcium homeostasis |
Multiple cellular models |
PF 3.33 |
STAT1 translocation |
Multiple cellular models |
PF 3.36 |
STAT2 translocation |
Multiple cellular models |
PF 3.35 |
STAT3 translocation |
Multiple cellular models |
PF 3.37 |
STAT5 phosphorylation |
Multiple cellular models |
PF 10.35 |
STAT6 phosphorylation |
Multiple cellular models |
PF 3.34 |
Poly-Ubiquitin detection |
Multiple cellular models |
PF 3.28 |
S6 RP expression/phosphorylation |
Multiple cellular models |
PF 10.42 |
c-Jun phosphorylation |
Multiple cellular models |
PF 10.41 |
mTOR phosphorylation |
Multiple cellular models |
PF 10.40 |
CREB phosphorylation |
Multiple cellular models |
PF 3.27 |
PKCα activation |
Multiple cellular models |
PF 10.39 |
Rb phosphorylation |
Multiple cellular models |
PF 10.38 |
AKT phosphorylation |
Multiple cellular models |
PF 10.7 |
FLIP expression |
HCT-116 cell line |
PF 10.27 |
Src expression |
Multiple cellular models |
PF 10.24 |
FRS2 phosphorylation |
MRT4 cell line |
PF 10.23 |
PLCy phosphorylation |
Multiple cellular models |
PF 10.21 |
Fas expression/phosphorylation |
Multiple cellular models |
PF 10.16 |
Prostate Specific Antigen (PSA) expression |
Multiple cellular models |
PF 10.15 |
VHL expression |
ACHN cell line |
PF 10.10 |
P130 CAS expression/phosphorylation |
ACHN cell line |
PF 10.11 |
FAK expression |
ACHN cell line |
PF 10.12 |